Mollie Leoni - 6Kura Oncology | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 35 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib for Relapsed/Refractory Peripheral T Cell Lymphoma

Thomas Witzig,Lubomir Sokol,Won Seog Kim,Fatima de la Cruz Vicente,Alejandro Martin Garcia-Sancho,Ranjana Advani, Jose Maria Roncero Vidal,Raquel de Ona Navarrete,Ana Marin-Niebla,Antonia Rodriguez Izquierdo,Maria Jose Terol,Eva Domingo-Domenech,

Blood advancesno. 17 (2024): 4581-4592

引用0浏览0WOS引用

Ziftomenib in Relapsed or Refractory Acute Myeloid Leukaemia (KOMET-001): a Multicentre, Open-Label, Multi-Cohort, Phase 1 Trial

Eunice S Wang,Ghayas C Issa,Harry P Erba,Jessica K Altman,Pau Montesinos, Stephane DeBotton,Roland B Walter,Kristen Pettit, Michael R Savona,Mithun Vinod Shah,Marina Kremyanskaya,Maria R Baer,

The Lancet Oncologyno. 10 (2024): 1310-1324

引用0浏览0WOS引用

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Amer M. Zeidan,Amir T. Fathi,Ghayas C. Issa,Harry P. Erba,JR Mackey,Daniel Corum,Blake Tomkinson,Tom Kozlek,Mollie Leoni,Eunice S. Wang

HemaSphereno. S3 (2023): e56956b1-e56956b1

引用0浏览0引用

Phase 1 Study of Ziftomenib (KO-539) in Combination with Venetoclax or Venetoclax/azacitidine or Standard Induction Cytarabine/daunorubicin (7+3) Chemotherapy for the Treatment of Patients with Acute Myeloid Leukemia

Amer Methqal Zeidan,Amir Tahmasb Fathi,Ghayas C. Issa,Harry Paul Erba,Julie Ahsan,Daniel Corum, Blake E. Tomkinson,Tom Kozlek,Mollie Leoni,Eunice S. Wang

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

KOMET-007 Trial in Progress: A Phase I Study of Ziftomenib in Combination With Venetoclax or Venetoclax/ Azacitidine, or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib, for the Treatment of Patients With Acute Myeloid Leukemia

Amer Zeidan,Amir Fathi,Ghayas Issa,Harry Erba,Julie Mackey Ahsan,Daniel Corum,Blake Tomkinson,Tom Kozlek,Mollie Leoni,Eunice Wang

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S308-S309

引用0浏览0引用

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

Amir Fathi,Eunice Wang,Ghayas Issa,Jessica Altman,Pau Montesinos,Stéphane de Botton,Roland Walter, Kirsten Pettit,Mrinal Patnaik,Marina Kremyanskaya,Maria Baer,James M Foran,

HemaSphereno. S3 (2023)

引用1浏览0引用

Komet-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia

Aaron D. Goldberg,Daniel Corum,Julie Ahsan, Kun Nie,Tom Kozlek,Mollie Leoni,Stephen Dale

Blood (2023): 1553

引用0浏览0引用

Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML

Harry Erba,Eunice Wang,Ghayas Issa,Jessica Altman,Pau Montesinos, Stephane DeBotton,Roland Walter, Kristin Pettit,Stephen Strickland,Mrinal Patnaik,Marina Kremyanskaya,Maria Baer,

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S304-S305

引用0浏览0引用

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma

Niamh Coleman,Kathrina L. Marcelo,Julia F. Hopkins,Nusrat Israr Khan,Robyn Du,Lingzhi Hong,Edward Park,Binaifer Balsara,Mollie Leoni,Curtis Pickering,Jeffrey Myers,John Heymach,

JCO Precis Oncol（2023）

引用5浏览0WOS引用

Abstract CT253: A Phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA-mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT trial)

Glenn J. Hanna, Cesar Perez Batista,Alan L. Ho,Maura L. Gillison,Douglas Adkins,Ashley Dayoub,Bridget Martell,Mollie Leoni,Stephen Dale, Kun Nie,Alex Dmitrienko

Cancer Researchno. 12_Supplement (2022)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn